6,8-Difluoro-1-(2-fluoroethyl)-7-(4-methylpiperazin-1-yl)-4-oxoquinoline-3-carboxylic acid;1-ethyl-6-fluoro-7-(4-methylpiperazin-1-yl)-4-oxoquinoline-3-carboxylic acid

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: 6,8-Difluoro-1-(2-fluoroethyl)-7-(4-methylpiperazin-1-yl)-4-oxoquinoline-3-carboxylic acid;1-ethyl-6-fluoro-7-(4-methylpiperazin-1-yl)-4-oxoquinoline-3-carboxylic acid
• 英文别名: 6,8-difluoro-1-(2-fluoroethyl)-7-(4-methylpiperazin-1-yl)-4-oxoquinoline-3-carboxylic acid;1-ethyl-6-fluoro-7-(4-methylpiperazin-1-yl)-4-oxoquinoline-3-carboxylic acid
• 化学式: C34H38F4N6O6
• 分子量: 702.7
• InChiKey: NRMXFMOXPZREJY-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.31
• 重原子数：
  50
• 可旋转键数：
  7
• 环数：
  6.0
• sp3杂化的碳原子比例：
  0.41
• 拓扑面积：
  128
• 氢给体数：
  2
• 氢受体数：
  16

文献信息

• AN ANTI-CERAMIDE ANTIBODIES
  申请人：Sloan-Kettering Institute for Cancer Research

  公开号：EP3903820A1

  公开（公告）日：2021-11-03

  It has been discovered that administering therapeutically effective amounts of an antibiotic that kills Gram-negative bacteria, together with an anti-ceramide antibody or anti-ceramide mimetic, treats and prevents an array of diseases mediated by cytolytic T lymphocyte (CTL)-induced killing and/or by damage to endothelial microvasculature, including Radiation GI syndrome, GvHD disease, inflammatory diseases and autoimmune diseases.

  研究发现，将治疗有效量的可杀死革兰氏阴性细菌的抗生素与抗神经酰胺抗体或抗神经酰胺仿制药一起服用，可治疗和预防一系列由细胞溶解性 T 淋巴细胞（CTL）诱导的杀伤和/或内皮微血管损伤介导的疾病，包括辐射性消化道综合征、GvHD 疾病、炎症性疾病和自身免疫性疾病。
• METHODS FOR TREATING GI SYNDROME AND GRAFT VERSUS HOST DISEASE
  申请人：Sloan Kettering Institute For Cancer Research

  公开号：EP2854850A2

  公开（公告）日：2015-04-08
• Methods for Treating GI Syndrome and Graft versus Host Disease
  申请人：SLOAN KETTERING INSTITUTE FOR CANCER Memorial Sloan Kettering Cancer Center

  公开号：US20150216971A1

  公开（公告）日：2015-08-06

  It has been discovered that administering therapeutically effective amounts of an antibiotic that kills Gram-negative bacteria, together with an anti-ceramide antibody or anti-ceramide mimetic, treats and prevents an array of diseases mediated by cytolytic T lymphocyte (CTL)-induced killing and/or by damage to endothelial microvasculature, including Radiation GI syndrome, CGvHD disease, inflammatory diseases and autoimmune diseases.
• [EN] METHODS FOR TREATING GI SYNDROME AND GRAFT VERSUS HOST DISEASE<br/>[FR] MÉTHODES DE TRAITEMENT DU SYNDROME GASTRO-INTESTINAL ET DE LA MALADIE DU GREFFON CONTRE L'HÔTE
  申请人：SLOAN KETTERING INST CANCER

  公开号：WO2013177596A2

  公开（公告）日：2013-11-28

  It has been discovered that administering therapeutically effective amounts of an antibiotic that kills Gram-negative bacteria, together with an anti-ceramide antibody or anti-ceramide mimetic, treats and prevents an array of diseases mediated by cytolytic T lymphocyte (CTL)-induced killing and/or by damage to endothelial microvasculature, including Radiation GI syndrome, GvHD disease, inflammatory diseases and autoimmune diseases.